Powered by

Exicure Expands Leadership Team with Appointment of TLR9 Oncology Expert Matthias Schroff as Chief Operating Officer

Apr 20, 2018 - Business Wire
Board and Executive Moves

Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional spherical nucleic acid (SNA(TM)) constructs, today announced the appointment of Matthias Schroff, Ph.D., to Chief Operating Officer. Dr. Schroff is a biotechnology industry veteran who brings more than 15 years of senior leadership experience within global biopharmaceutical companies where he gained deep scientific and clinical experience in immuno-oncology, TLR9 biology and broad clinical progr...